These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32000886)

  • 1. No effect of norepinephrine dose on anti-Xa activity in critically ill patients
.
    Meenks SD; Foudraine NA; Broen K; le Noble JLML; Janssen PKC
    Int J Clin Pharmacol Ther; 2020 Apr; 58(4):223-229. PubMed ID: 32000886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
    Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
    J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study.
    Rommers MK; Van der Lely N; Egberts TC; van den Bemt PM
    Crit Care; 2006; 10(3):R93. PubMed ID: 16790078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism.
    Damle B; Jen F; Sherman N; Jani D; Sweeney K
    J Clin Pharmacol; 2021 Feb; 61(2):172-180. PubMed ID: 32827160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
    Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M;
    Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioactivity of enoxaparin in critically ill patients with normal renal function.
    Gouya G; Palkovits S; Kapiotis S; Madl C; Locker G; Stella A; Wolzt M; Heinz G
    Br J Clin Pharmacol; 2012 Nov; 74(5):806-14. PubMed ID: 23227470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
    Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
    Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism.
    Wilson SJ; Wilbur K; Burton E; Anderson DR
    Haemostasis; 2001; 31(1):42-8. PubMed ID: 11408748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
    Rabbat CG; Cook DJ; Crowther MA; McDonald E; Clarke F; Meade MO; Lee KA; Cook RJ
    J Crit Care; 2005 Dec; 20(4):357-63. PubMed ID: 16310608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients.
    Kovacs MJ; Levine MN; Keeney M; Mackinnon KM; Lee AY
    Thromb Haemost; 2005 Jun; 93(6):1185-8. PubMed ID: 15968406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).
    Collignon F; Frydman A; Caplain H; Ozoux ML; Le Roux Y; Bouthier J; Thébault JJ
    Thromb Haemost; 1995 Apr; 73(4):630-40. PubMed ID: 7495071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patients.
    van der Heijden CDCC; Ter Heine R; Kooistra EJ; Brüggemann RJ; Walburgh Schmidt JWJ; de Grouw EPLM; Frenzel T; Pickkers P; Leentjens J
    Br J Clin Pharmacol; 2022 Jun; 88(6):2982-2987. PubMed ID: 34965610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ATLANTIC study: Anti-Xa level assessment in trauma intensive care.
    Rakhra S; Martin EL; Fitzgerald M; Udy A
    Injury; 2020 Jan; 51(1):10-14. PubMed ID: 31679829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients.
    Stattin K; Lipcsey M; Andersson H; Pontén E; Bülow Anderberg S; Gradin A; Larsson A; Lubenow N; von Seth M; Rubertsson S; Hultström M; Frithiof R
    J Crit Care; 2020 Dec; 60():249-252. PubMed ID: 32920503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism.
    O'Brien SH; Kulkarni R; Wallace A; Hamblin F; Burr S; Goldenberg NA
    J Thromb Haemost; 2014 Nov; 12(11):1822-5. PubMed ID: 25182454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of subcutaneous dalteparin in patients with renal insufficiency under intensive care: an observational study.
    Kani C; Markantonis SL; Nicolaou C; Maggina N
    J Crit Care; 2006 Mar; 21(1):79-84. PubMed ID: 16616629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twice-Daily Enoxaparin among Plastic Surgery Inpatients: An Examination of Pharmacodynamics, 90-Day Venous Thromboembolism, and 90-Day Bleeding.
    Pannucci CJ; Fleming KI; Momeni A; Prazak AM; Agarwal J; Rockwell WB
    Plast Reconstr Surg; 2018 Jun; 141(6):1580-1590. PubMed ID: 29608533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment.
    Woodruff S; Feugère G; Abreu P; Heissler J; Ruiz MT; Jen F
    J Thromb Thrombolysis; 2016 Nov; 42(4):494-504. PubMed ID: 27344439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic Comparison of Subcutaneous and Intravenous Nadroparin Administration for Thromboprophylaxis in Critically Ill Patients on Vasopressors.
    Cihlar R; Sramek V; Papiez A; Penka M; Suk P
    Pharmacology; 2020; 105(1-2):73-78. PubMed ID: 31578015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy.
    Jacobsen AF; Qvigstad E; Sandset PM
    BJOG; 2003 Feb; 110(2):139-44. PubMed ID: 12618157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.